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Preface 
 
The medical screening for tuberculosis among persons overseas applying for U.S. 
immigration status and nonimmigrants who are required to have an overseas medical 
examination, hereafter referred to as applicants, is an essential component of the medical 
evaluation. Because tuberculosis is a challenging disease to diagnose, treat, and control, these 
instructions are designed to detect and treat tuberculosis disease among applicants and to 
reduce the risk of spread of tuberculosis among the U.S. population after immigration.  
 
The instructions in this document supersede all previous Technical Instructions, Updates to 
the Technical Instructions, memoranda and letters to panel physicians, and memoranda and 
letters to international refugee resettlement organizations. These instructions are to be 
followed for tuberculosis screening and treatment among all applicants.  
 
For any questions about these Technical Instructions, please contact the Immigrant, 
Refugee, and Migrant Health Branch of the Division of Global Migration and Quarantine 
(DGMQ), Centers for Disease Control and Prevention (CDC), at cdcQAP@cdc.gov or 404-
498-1600.  These Technical Instructions and other information pertinent to them and the 
medical examination for applicants for U.S. immigration can be found online at 
http://www.cdc.gov/ncidod/dq/panel_2007.htm.   
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Tuberculosis Screening 
 
 
Any applicant for whom the clinical suspicion of tuberculosis is high enough  
to warrant treatment for tuberculosis disease, regardless of laboratory results,  
is considered to have tuberculosis disease and is Class A for Tuberculosis. 
 
 
 
Applicants 2-14 years of age living in countries with a World Health Organization 
(WHO)-estimated tuberculosis incidence rate of ≥20 cases per 100,000 population 
should have a tuberculin skin test or an interferon gamma release assay.   
 
 
 
Prior receipt of Bacille Calmette-Guérin (BCG) vaccination  
does not change the screening requirements or the required actions  
based on tuberculin skin test results. 
 
 
A complete screening medical examination for tuberculosis consists of a medical history, 
physical examination, chest radiography (CXR, when required), determination of immune 
response to Mycobacterium tuberculosis antigens (i.e., tuberculin skin testing [TST] or interferon 
gamma release assay [IGRA], when required), and sputum testing for M. tuberculosis (when 
required, Figures 1 and 2).  
 
Applicants ≥15 years of age require a medical history, physical examination, and CXR.  If an 
applicant has a CXR with findings suggestive of tuberculosis (page 5), has signs and 
symptoms of tuberculosis (page 5), or has human immunodeficiency virus (HIV) infection, 
the applicant should provide three sputum specimens to undergo microscopy for acid fast 
bacilli (AFB), as well as culture for mycobacteria and confirmation of the Mycobacterium 
species, at least to the M. tuberculosis complex level.   
 
Applicants 2-14 years of age living in countries with a World Health Organization (WHO)-
estimated tuberculosis incidence rate of ≥20 cases per 100,000 population should have a 
TST or an IGRA.  If the TST is ≥10 mm or the IGRA is positive or if the applicant has 
signs and symptoms of tuberculosis or has HIV, a CXR (anteroposterior or posteroanterior 
view and a lateral view for applicants <10 years of age; posteroanterior view for applicants 
≥10 years of age) should be performed.  Applicants who have a CXR with findings 
suggestive of tuberculosis, signs and symptoms of tuberculosis, or HIV infection should 
provide three sputum specimens to undergo microscopy for AFB, as well as culture for 
mycobacteria and confirmation of the Mycobacterium species, at least to the M. tuberculosis 
complex level. 
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All applicants <2 years of age living in countries with a WHO-estimated tuberculosis 
incidence rate of ≥20 cases per 100,000 population must have a physical examination and 
history provided by a parent or responsible adult who knows the child best. Those applicants 
who have signs or symptoms suggestive of tuberculosis or have HIV should have a TST or 
an IGRA, a CXR (anteroposterior or posteroanterior view and a lateral view), and provide 
three sputum specimens to undergo microscopy for AFB, as well as culture for mycobacteria 
and confirmation of the Mycobacterium species, at least to the M. tuberculosis complex level.  
Information about sputum collection in young children can be found in the Laboratory 
Testing section (Page 6) and in Appendix C.   
 
All applicants <15 years of age living in countries with a WHO-estimated tuberculosis 
incidence rate of <20 cases per 100,000 population must have a physical examination and 
history provided by a parent or responsible adult who knows the child best.  Those 
applicants who have signs or symptoms suggestive of tuberculosis or have HIV should have 
a TST or an IGRA, a CXR (anteroposterior or posteroanterior view and a lateral view for 
applicants <10 years of age; posteroanterior view for applicants ≥10 years of age) and 
provide three sputum specimens to undergo microscopy for AFB, as well as culture for 
mycobacteria and confirmation of the Mycobacterium species, at least to the M. tuberculosis 
complex level. 
 
Pulmonary tuberculosis is a disease that involves the lung parenchyma and is often infectious 
(i.e., contagious [determined by sputum smear examination for AFB and mycobacterial 
culture]).  Laryngeal tuberculosis is rare but highly infectious.  Disease of the lung 
parenchyma may occur concurrently with pleural tuberculosis, and the parenchymal lung 
disease may not be apparent on chest radiograph due to compression of affected lung tissue 
by pleural fluid.  Because the emphasis for pre-immigration medical evaluation is on 
infectiousness, for the purpose of this document the term pulmonary tuberculosis refers to 
disease of the lung parenchyma, pleural tuberculosis, and laryngeal tuberculosis.   
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For applicants ≥15 years of age
Medical history  
Physical examination 
Chest radiograph
Medical history, examination, or chest radiograph 
suggestive of tuberculosis or HIV infection 
Three sputum smears and cultures for 
Mycobacterium tuberculosis 
Drug susceptibility testing  
on positive culture 
 
Figure 1: Tuberculosis screening medical examination for applicants 15 years of age in 
countries with a WHO-estimated tuberculosis incidence rate <20 cases per 100,000 
population. 
 
Tuberculosis Screening and Treatment 3  
Technical Instructions for Panel Physicians   
 
Tuberculosis Screening and Treatment 4  
For applicants 
2 – 14 years of age 
For applicants 
≥15 years of age 
Medical history 
Physical examination 
Medical history  
Physical examination 
Tuberculin skin test 
or 
IGRA 
Chest radiograph 
TST ≥10 mm 
or 
IGRA positive Medical history, examination, or 
chest radiograph suggestive of 
tuberculosis or HIV infection 
Three sputum smears and cultures 
for Mycobacterium tuberculosis 
 
Drug susceptibility testing  
of positive cultures 
 
Figure 2: Tuberculosis screening medical examination for applicants ≥2 years of age in 
countries with a WHO-estimated tuberculosis incidence rate ≥20 cases per 100,000 
population. 
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Each aspect of the examination is detailed below: 
 
Medical History 
 The medical history should focus on risk factors for tuberculosis disease, including 
previous history of tuberculosis; illness suggestive of tuberculosis (such as cough of 
>3 weeks’ duration, dyspnea, weight loss, fever, or hemoptysis); prior treatment 
suggestive of tuberculosis treatment; and prior diagnostic evaluation suggestive of 
tuberculosis. The clinical expression of tuberculosis may be different in children than 
adults, and for children may only include generalized findings such as fever, night 
sweats, growth delay, and weight loss. Children are also more prone to 
extrapulmonary tuberculosis, such as meningitis, and disease of the middle ear and 
mastoid, lymph nodes, bones, joints, and skin.  
 The medical history should also include inquiries regarding family or household 
contact with a person who has or had tuberculosis or illness, treatment, or diagnostic 
evaluation suggestive of tuberculosis.  
 Prior receipt of Bacille Calmette-Guérin (BCG) vaccination should be ascertained; 
review and record if documentation and date of receipt are available.  
 
Physical Exam 
 Pertinent elements of the physical exam for tuberculosis include general 
characteristics such as height, weight, temperature, heart rate, respiratory rate, and 
blood pressure; a thorough pulmonary examination; inspection and palpation of 
appropriate lymph nodes; and inspection for scars of scrofula and prior chest 
surgery. 
 
Chest Radiography 
When performed, chest radiography (CXR) should consist of a standard posteroanterior 
view for all applicants 10 years of age.  Applicants <10 years of age who receive a CXR 
should have a standard anteroposterior or standard posteroanterior view and should also 
have a lateral view.  If a child receives a posteroanterior view, the CXR should be labeled 
“PA” for the benefit of radiologist’s review.   
 
Chest radiographs should be interpreted by a radiologist and reviewed by the panel 
physician.  Documentation of the results for the chest radiographs should be available within 
1 week from the time the CXR was performed.  CXRs of any applicants, especially children, 
should be re-taken if the initial CXR is suboptimal due to factors such as incorrect 
penetration or motion artifact.  CXR interpretations should include comparisons with prior 
CXRs, if available. 
 
Women who are pregnant are required to have a CXR to immigrate.  Pregnant women must 
provide consent for the CXR. Pregnant women receiving chest radiographs should be 
provided abdominal and pelvic protection with double-layer, wrap-around lead shields.  
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Immune Response to M. tuberculosis Antigens 
 Applicants 2-14 years of age living in countries with a WHO-estimated tuberculosis 
incidence rate of ≥20 cases per 100,000 population should have determination of 
immune response to M. tuberculosis antigens through placement of a TST or 
performance of an IGRA.   Exceptions include applicants with written 
documentation from a physician of a previous TST reaction ≥10 mm or a positive 
IGRA.  For TST, the written documentation must include date of the test, 
millimeters of induration, type of PPD used, and the testing physician’s name and 
office information.  For IGRA, the written documentation must include date of the 
test, type of IGRA performed, test results in standard units of measurement, the test 
interpretation (e.g., positive, negative, indeterminate, borderline), and the testing 
physician’s name, signature and office information.  Applicants 2-14 years of age 
with a documented previous history of tuberculosis disease should have a CXR, even 
if their TST <10 mm or IGRA is negative.   
Panel physicians should be advised that some experts prefer TST in children younger 
than 5 years of age.  There are relatively few published reports documenting the 
performance of IGRAs in young children, obtaining sufficient blood is more 
difficult, and there is concern that IGRAs may perform differently in very young 
children who are at greater risk of a poor outcome if infection is undiagnosed. 
 TST 
Purified protein derivative (PPD) should be administered intradermally by the 
Mantoux method.  Ideally, preparations used should be equivalent to 5TU PPD-
S.  However, in countries where such preparations are limited or impossible to 
import, panel physicians should use PPD preparations that are approved for use 
by their Ministries of Health.  The type of PPD used should be documented.  
 IGRA 
Interferon gamma release assays are blood tests that measure a component of 
cell-mediated immune reactivity to M. tuberculosis in fresh whole blood.  CDC 
allows the use of QuantiFERON®-TB Gold (QFT-G), QuantiFERON®-TB 
Gold In Tube (QFT-G IT), or T-SPOT® by panel physicians.  Panel physicians 
should follow the manufacturers’ written instructions for performing the 
examinations and interpreting test results.  For the purpose of tuberculosis 
screening according to these Technical Instructions, an indeterminate test result 
should be viewed as a negative result.  However, applicants with an 
indeterminate test result should be advised to have a repeat test after arrival to 
the United States.  IGRA test results in their unit of measurement should be 
documented, even for those with negative or indeterminate results.   
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Laboratory Testing 
 Laboratory examination for tuberculosis disease should consist of at least three 
sputum specimens, which should undergo microscopy for AFB as well as culture for 
mycobacteria and confirmation of the Mycobacterium species, at least to the M. 
tuberculosis complex level (Appendix B, Appendix C).  Specimens reported as negative 
should be cultured for a minimum of 6 weeks, with a final report produced within 8 
weeks of collection.  Positive cultures need to be reported as soon as the results are 
known.   
 Applicants unable to produce sputum specimens, such as young children, are 
required to have alternative methods of sputum collection performed (e.g., early 
morning gastric aspirates or sputum induction or both [Appendix C]) to determine 
their tuberculosis status.  
 Positive M. tuberculosis cultures shall undergo drug susceptibility testing (DST) for 
isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin.  Panel physicians 
must have access to DST results within 10 weeks of sputum collection.  
 Positive M. tuberculosis cultures that are resistant to isoniazid and rifampin shall 
undergo drug susceptibility testing on second-line tuberculosis medications.  At a 
minimum, second-line testing should include testing for resistance against 
ethionamide, a fluoroquinolone (e.g., ofloxacin, levofloxacin, moxifloxacin), 
amikacin, capreomycin, and para-aminosalycilic acid (PAS).   
 The laboratory requirements in these instructions do not preclude panel physicians 
from using additional tests for tuberculosis that they may have access to, such as the 
Hain GenoType® MTBDRplus assay.  Panel physicians should only use only tests 
that have garnered regulatory approval in the country in which they would be used 
and only use the tests only for the purposes for which they have been approved.  
Panel physicians may base treatment decisions on the results of regulatory-approved 
tests for tuberculosis.    
 
In addition to the recommendations provided, panel physicians should use their clinical 
judgment in the evaluation and treatment of the applicant. 
 
Many applicants may have previously received BCG vaccination.  Prior receipt of BCG does 
not change the screening requirements or the required actions based on those results.   
 
Detection of tuberculosis disease necessitates a combined clinical and public health response 
to cure individual tuberculosis patients, stop transmission, and enable safe movement to the 
United States.  
 
For additional guidance for resettlement of large refugee groups, see Appendix E.  
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The evaluation is complete when all required aspects of the medical examination 
have been completed, including a final report of culture results, and the applicant 
can be assigned a Tuberculosis Classification.    
 
 
 
Travel clearances are valid for 6 months from the time the evaluation is complete 
for applicants who have no Tuberculosis Classification or only Class B2 TB or 
Class B3 TB and who do not have HIV infection.  
 
 
 
Travel clearances are valid for 3 months from the time the evaluation is complete 
for applicants who are Class B1 TB, Pulmonary or Class B1 TB, Extrapulmonary 
or who have HIV infection. 
 
 
 
Applicants who do not travel within the clearance period will need  
to restart the tuberculosis screening process. 
 
 
 
Any applicant diagnosed with pulmonary or laryngeal tuberculosis who needs 
treatment is not cleared for travel until completion of successful treatment, 
regardless of the diagnostic criteria.  
 
 
It is important that tuberculosis disease be correctly diagnosed among applicants for U.S. 
immigration. Correct diagnosis of tuberculosis will ensure that applicants with tuberculosis 
disease receive correct treatment, reduce further spread of the disease, and reduce the 
likelihood of treating applicants who do not have the disease, thus unnecessarily delaying 
their immigration.  
 
Applicants with clinical and radiographic findings suggestive of common bacterial infections 
of the upper and lower respiratory tract may be treated with a course of antibiotics. 
However, fluoroquinolones should not be used for empiric treatment of respiratory 
infections because they are a mainstay of second-line tuberculosis therapy and their use 
could both result in mistreatment of tuberculosis and lead to drug-resistant tuberculosis. 
After treatment for lower respiratory infections, the CXR for medical screening should not 
be performed until at least 8 weeks after therapy, unless the applicant’s clinical status 
warrants further evaluation earlier than 8 weeks after therapy.  Table 1:  Tuberculosis screening 
results, travel clearance, and actions lists screening results and required actions for those results.  
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Table 1: Tuberculosis screening results, travel clearance, and actions. 
 
Medical 
History 
Physical 
Exam 
Chest 
Radiograph 
TST or 
IGRA*  
Sputum 
Smears 
Culture for 
Mycobacterium
Travel 
Clearance 
Action or TB Classification† 
Normal Normal Normal Negative NA NA 6 months‡ No TB Classification 
Normal Normal Normal Positive NA NA 6 months‡ Class B2 TB, LTBI Evaluation 
Normal Normal Normal Negative Negative Negative 3 months§ No TB Classification 
Normal Normal Normal Positive Negative Negative 3 months§ Class B2 TB, LTBI Evaluation¶ 
Normal Normal Normal 
Negative 
or Positive 
Either positive No Class A, Treatment 
Any component suggestive of TB Negative 
or Positive 
Negative  Negative No Use clinical judgment¶. 
Any component suggestive of TB Negative 
or Positive 
Either positive No Class A Treatment 
Any component suggestive of TB Negative 
or Positive 
Negative  Negative No Use clinical judgment¶. 
Any component suggestive of TB Negative 
or Positive 
Either positive No Class A, Treatment 
Completed therapy for tuberculosis Negative 
or Positive 
Negative or 
Positive 
Negative 3 months§ Class B1 TB, Pulmonary 
Completed therapy for tuberculosis Negative 
or Positive 
Negative or 
Positive 
Negative 3 months§ Class B1 TB, Pulmonary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* When required.  TST and IGRA results have no bearing on travel clearance.  
† All contacts must receive a Class B3 TB, Contact Evaluation classification unless they are Class A or have extrapulmonary disease. 
‡ From the time the evaluation is complete.  
§  Travel clearance is for 3 months from the time the evaluation is complete; culture results must be known within 8 weeks of collection. 
¶   Tuberculosis treatment should not be initiated for applicants who are smear- and culture-negative unless the CXR and clinical findings 
are highly suggestive of tuberculosis disease.  If cleared to travel, their tuberculosis classification will be Class B1 TB, Pulmonary. 
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Screening Results and Travel Clearance 
 Applicants without clinical findings of tuberculosis, without HIV infection, and with a 
normal CXR (and for children 2-14 years of age, a TST <10 mm or negative IGRA) can be 
cleared for travel to the United States (Table 1). Applicants should be assigned a tuberculosis 
classification (No TB Classification). 
 
 Applicants 2-14 years of age who have a TST ≥10 mm or a positive IGRA and are without 
HIV infection, have no clinical findings of tuberculosis, and have a normal CXR can be 
cleared for travel to the United States. Such applicants should be assigned a tuberculosis 
classification to receive evaluation for LTBI in the United States (Class B2 TB, LTBI 
Evaluation). 
 
 Applicants with signs or symptoms suggestive of tuberculosis, a CXR suggestive of 
tuberculosis disease, or HIV infection shall have three sputum specimens to undergo 
microscopy for acid-fast bacilli (AFB), as well as culture for mycobacteria and confirmation 
of the Mycobacterium species, at least to the M. tuberculosis complex level. Any laboratory or 
additional studies shall be performed that are deemed necessary, either as a result of the 
physical examination or pertinent information elicited from the applicant's medical history 
for the panel physician to reach a conclusion about the presence or absence of tuberculosis 
(TB classification pending). 
 
 Applicants with HIV infection should have three sputum specimens sent to the laboratory 
for AFB microscopy and culture. These applicants cannot be cleared for travel until the 
results of the laboratory investigation are available (TB classification pending). 
 
 Applicants who have sputum smears that are positive for AFB microscopy should not be 
cleared for travel and should be started on treatment for tuberculosis disease (Class A TB).  
If the culture results are negative or demonstrate nontuberculous mycobacteria (NTM), 
panel physicians should use their clinical judgment in determining whether to continue 
treatment for tuberculosis disease.  If applicants have NTM and the panel physician does not 
feel further treatment for tuberculosis disease is warranted, those applicant may be cleared 
for travel.  The presence of NTM should be documented on the DS Forms.  Applicants who 
had an abnormal CXR or signs and symptoms suggestive of tuberculosis disease should be 
assigned a Class B1 TB, Pulmonary classification. 
 
 Applicants who have negative sputum smears and positive M. tuberculosis cultures should not 
be cleared for travel and should be treated for tuberculosis (Class A TB). 
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 Applicants diagnosed with extrapulmonary tuberculosis only (except for laryngeal or pleural 
tuberculosis) can be cleared for travel. Applicants should be assigned a tuberculosis 
classification (Class B1 TB, Extrapulmonary). Efforts should be made to obtain a laboratory-
confirmed diagnosis.  Applicants with extrapulmonary tuberculosis should be considered for 
treatment if departure is not planned within 3 months or if withholding therapy would be 
harmful.  Applicants with extrapulmonary disease who are started on therapy prior to 
departure should be instructed of the importance of completing therapy after their arrival in 
the United States. They should be given a 14-day supply of medication at departure.  
Because patients with laryngeal and pleural tuberculosis can be infectious, they must 
complete therapy before departure.   
 
 A diagnosis of extrapulmonary tuberculosis does not preclude an evaluation for pulmonary 
tuberculosis within the specified time frames.  Applicants with extrapulmonary tuberculosis 
(except for laryngeal and pleural tuberculosis) do not have to provide sputum smears unless 
they have signs or symptoms suggestive of tuberculosis disease, an abnormal CXR 
suggestive of tuberculosis, or have HIV infection.  
 
 Applicants who have negative sputum smears and cultures, but have one of the cultures 
reported as “contaminated,” may still be cleared for travel.  When applicants have >1 
contaminated cultures, panel sites and their designated laboratories should review their 
procedures and collect three additional sputum specimens from the applicant for AFB 
microscopy and culture.    
 
 Applicants diagnosed with tuberculosis disease by panel physicians and who are not treated 
at treatment centers approved by DGMQ should not be cleared for travel.  These applicants 
will need to repeat their medical screening examination 1 year after treatment was 
completed.   If the tuberculosis examination is negative at that time, the applicant can be 
cleared for travel.  The applicant should receive a Class B1 TB, Pulmonary classification, and 
their treatment location, including physician name and clinic city and state, should be 
documented on the DS Forms.  A written treatment summary must be presented by the 
applicant from the treating provider and attached to the travel documents of the applicant.     
 
 Applicants 10 years of age or younger who require sputum cultures, regardless of HIV 
infection status, may travel to the United States immediately after sputum smear analysis 
(while culture results are pending) if none of the following conditions exist: 
o Sputum smears are positive for acid-fast bacilli (AFB).  If the applicant could not 
provide sputum specimens and gastric aspirates were obtained, positive gastric aspirates 
for AFB do not prevent travel while culture results are pending.   
o Chest radiograph findings include―  
 One or more cavities 
 Extensive disease (e.g., particularly if involving both upper lobes) 
o Respiratory symptoms include forceful and productive cough 
o Known contact with a person with multidrug-resistant tuberculosis (MDR TB) who was 
infectious at the time of contact 
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For applicants 10 years of age or younger who travel to the United States while results of 
cultures are pending, panel physicians should― 
o Give the applicant a Class B1 TB, Pulmonary classification 
o Document that culture results are pending on the Chest X-Ray Worksheet (DS 3030)  
o Forward culture results to DGMQ “Quality Assessment Program” via fax at 404-639-
4441 so that DGMQ can forward the culture results to the receiving health departments 
 
For applicants 10 years of age and younger, panel physicians should provide the DS Forms 
based on the date of intended travel.  If an applicant 10 years of age or younger will not 
travel until after culture results are to be reported (assuming they are negative), the panel 
physicians should wait until that time before completing the DS Forms.  If the applicant 10 
years of age or younger will travel while results of cultures are pending, the panel physician 
should provide DS Forms while cultures are pending.   
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Tuberculosis Treatment 
 
 
All applicants with pulmonary or laryngeal tuberculosis disease who need treatment 
overseas will need to complete directly observed therapy (DOT) prior to U.S. immigration. 
 
 
 
Applicants diagnosed with possible tuberculosis disease who are smear and culture 
negative should not have treatment begun overseas unless the CXR and clinical findings  
are highly suggestive of tuberculosis disease. 
 
 
 
Follow current ATS/CDC/IDSA guidelines 
(http://www.cdc.gov/tb/pubs/mmwr/Maj_guide/Treatment.htm).   
 
 
 
Use only quality-assured drugs. Consult the World Health Organization (WHO) Global 
Drug Facility (GDF) for first-line drugs and the International Dispensary Association (IDA, 
Amsterdam) or WHO Green Light Committee for second-line drugs.  
 
 
 
For panel physicians not wanting to treat tuberculosis patients themselves,  
the Division of Global Migration and Quarantine will identify national  
or other in-country programs that follow these standards.   Treatment will need to be 
supervised by panel physicians using these standards or by programs identified  
by the Division of Global Migration and Quarantine. 
 
 
Treatment of tuberculosis, both pulmonary and extrapulmonary, should be administered following 
DOT policies and practices during the entire course of therapy.  DOT is an adherence-enhancing 
strategy in which a health-care worker or other trained person watches a patient swallow each dose 
of medication.  Directly observed therapy is the standard care for all applicants with tuberculosis 
disease.  
 
Applicants with positive sputum smears or positive cultures who do not want to be treated may not 
travel to the United States.  Panel physicians should notify the Consulate of any Class A applicants 
refusing tuberculosis treatment at a designated DOT facility.  The panel physician has an ethical 
obligation to make good-faith efforts to treat patients, including notifying public health officials if 
efforts to treat them fail.  Panel physicians should notify the appropriate public health officials in 
their jurisdiction when they diagnose an applicant with tuberculosis disease. 
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Applicants, including children, who are diagnosed with possible tuberculosis disease but have 
negative sputum smears and negative cultures, can be given consideration for not initiating therapy 
prior to departure.  Treatment should only be initiated only if the CXR and clinical findings are 
highly suggestive of tuberculosis disease.  Applicants who begin therapy under these circumstances 
should be re-evaluated clinically and radiographically after 2 months of treatment.  Treatment should 
be continued only if there is evidence of clinical and/or radiographic improvement.   
 
Treatment of U.S. applicants should be administered consistent with the current American Thoracic 
Society (ATS)/CDC/Infectious Diseases Society of America (IDSA) guidelines for treatment of 
tuberculosis, including being guided by drug-susceptibility testing results 
(http://www.cdc.gov/tb/pubs/mmwr/Maj_guide/Treatment.htm).  These guidelines are consistent 
with International Standards for Tuberculosis Care (Tuberculosis Coalition for Technical Assistance, 
The Hague: 2006).   Sites may not substitute local treatment standards for ATS/CDC/IDSA 
standards for these applicants.     
 
Identification of an applicant with multidrug-resistant tuberculosis (MDR TB) should be reported to 
DGMQ (cdcQAP@cdc.gov or fax: 404-639-4441) within 1 week of receipt of the DST report. 
 
Treatment of MDR TB should be done by or in close consultation with experts in the management 
of such cases and in coordination with DGMQ.  Panel physicians and DGMQ-identified treatment 
programs should have direct access to tuberculosis treatment expertise for consultation regarding 
care of complex tuberculosis cases.  DGMQ, in consultation with the Division of Tuberculosis 
Elimination (DTBE), will identify tuberculosis consultants.  Documentation of consultation with a 
tuberculosis expert should be maintained and forwarded by the panel physician to DGMQ within 1 
week of consultation.  Additional written guidance on treatment of drug-resistant tuberculosis can 
be found in “Drug-resistant tuberculosis: a survival guide for clinicians” by the Francis J. Curry 
National Tuberculosis Center and California Department of Health Services, San Francisco, 
California (http://www.nationaltbcenter.edu/products/product_details.cfm?productID=WPT-11).   
 
For applicants who present for the medical examination already on tuberculosis treatment begun 
elsewhere or for applicants diagnosed with tuberculosis who transfer into a DGMQ-designated 
DOT program, therapy should be continued in the following manner: 
 As soon as patients transfer into the DOT program, they should provide three sputum 
specimens for AFB analysis and culture.  Positive isolates should undergo drug susceptibility 
testing.  If drug resistance is detected, the patient’s regimen should be modified accordingly.  
 The patients should continue their treatment regimen according to the ATS/CDC/IDSA 
guidelines and provide sputum monitoring as described in these TB TI.    
 If the patient was being treated by using a WHO continuation phase of 6 months of 
isoniazid and ethambutol (which is not consistent with the ATS/CDC/IDSA guidelines): 
 If the applicant has completed 2 months or less of the 6-month isoniazid and 
ethambutol continuation phase (and has no drug resistance), the 6-month isoniazid and 
ethambutol continuation phase should be stopped and the patient should be started on 
the standard 4-month continuation phase of isoniazid and rifampin.  
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 If the patient has completed >2 months of the 6-month isoniazid and ethambutol 
continuation phase (and has no drug resistance), the patient should complete the 6-
month isoniazid and ethambutol continuation phase.  
 For the benefit of receiving health departments, for those patients who complete a 6-
month isoniazid and ethambutol continuation phase, please document that this is a 
WHO-approved regimen.   
 
For panel physicians who do not want to perform tuberculosis therapy, DGMQ will identify 
programs that adhere to these standards.  When applicants are sent for treatment to national or 
other in-country programs that are approved by DGMQ, panel physicians should collaborate with 
these designated treatment programs to help ensure adequate completion of therapy for the 
applicants.  
 
Applicants treated at non-DGMQ-designated treatment sites will need to provide documentation of 
their treatment summary to demonstrate having completed tuberculosis treatment.  A letter from a 
physician stating they were treated is not sufficient.  Documentation of treatment should include―  
 Medication names 
 Dosages of medications 
 Dates of delivery of each medication 
 Results of sputum smear, culture, and DST results performed by the nondesignated 
treatment center 
 Reports of CXR performed by the nondesignated treatment center 
 
Without this documentation, the applicant may not be further considered for travel to the United 
States.   
Technical Instructions for Panel Physicians   
Waivers  
 
 
A provision allows applicants undergoing pulmonary or laryngeal tuberculosis  
treatment to petition for a Class A waiver. 
 
 
 
Waivers should be pursued for any immigrant or refugee who has  
a complicated clinical course and would benefit from receiving  
tuberculosis treatment in the United States. 
 
 
 
Applicants diagnosed with tuberculosis disease who are both smear-  
and culture-negative and will be traveling to the United States  
prior to start of treatment do not need to complete the waiver process. 
 
 
In exceptional medical situations, a provision allows applicants undergoing pulmonary tuberculosis 
treatment to petition for a Class A waiver. Form I-601 or I-602 (for immigrants or refugees, 
respectively) must be completed.  These petitions are reviewed by the Department of Homeland 
Security on an individual basis and considered in situations with extenuating medical circumstances 
and also sent to DGMQ to also review.  DGMQ reviews the application and provides an opinion 
regarding the case to the requesting entity (DOS or DHS).  DHS then has the final authority to 
adjudicate the waiver request.  Because tuberculosis disease in young children is very challenging, 
CDC supports the filing of waiver requests for young children with tuberculosis disease so that the 
waiver request may be reviewed and adjudicated in a timely manner.   
 
All requests for waivers need to be accompanied by prior notification and approval by the U.S.-
based physician accepting responsibility for the applicant’s continued care and treatment and the 
U.S. health department with jurisdiction.   
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Tuberculosis Treatment Monitoring 
 
 
These guidelines in the Technical Instructions use drug-susceptibility testing results  
to determine the frequency of laboratory testing during drug treatment. 
 
 
 
Children <10 years of age with drug-susceptible or culture-negative tuberculosis who 
cannot provide sputum specimens will not need to provide induced sputum or gastric 
aspirate specimens during treatment, unless their clinical course warrants an evaluation.  
 
 
 
When signs of clinical worsening occur during therapy, such as persistent weight loss, 
fever, cough, or worsening CXR, repeat sputum smears, cultures, and DST are indicated.  
 
 
These guidelines for treatment monitoring differ from recommendations in the ATS/CDC/IDSA 
guidelines and “Drug-resistant tuberculosis:  a survival guide for clinicians” by the Francis J. Curry 
National Tuberculosis Center and California Department of Health Services. 
 
 Drug-susceptible: two sputum specimens should be collected and submitted for AFB 
microscopy and mycobacteria culture once a month during therapy until cultures are 
negative for 2 consecutive months.  Two sputum specimens should be collected and 
submitted for AFB microscopy and mycobacteria culture at the end of therapy.   
 Resistant to only one drug (including resistant to only isoniazid or rifampin): two 
sputum specimens should be collected and submitted for AFB microscopy and mycobacteria 
culture once a month during therapy until cultures are negative for 2 consecutive months.  
Two sputum specimens should be collected and submitted for AFB microscopy and 
mycobacteria culture at the end of therapy. 
 Resistant to more than one drug but susceptible to isoniazid or rifampin (drug 
resistant but not MDR TB): two sputum specimens should be collected and submitted for 
AFB microscopy and mycobacteria culture once a month during therapy until cultures are 
negative for 2 consecutive months.  Two sputum specimens should be collected and 
submitted for AFB microscopy and mycobacteria culture at the end of therapy. 
 MDR TB (resistant at least to both isoniazid and rifampin): two sputum specimens 
should be collected and submitted for AFB microscopy and mycobacteria culture once a 
month during therapy.  Two sputum specimens should be collected and submitted for AFB 
microscopy and mycobacteria culture at the end of therapy. 
 No drug susceptibility testing results (culture negative): one sputum specimen should 
be collected and submitted for AFB microscopy and mycobacteria culture once a month 
during therapy.  Two sputum specimens should be collected and submitted for AFB 
microscopy and mycobacteria culture at the end of therapy. 
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Contacts of Tuberculosis Cases 
 
 
Contacts of persons with pulmonary tuberculosis disease should be removed  
from exposure to the person with tuberculosis. 
 
 
 
All contacts should receive a TST or IGRA. 
 
 
 
Contacts who have clinical findings or CXR findings suggestive of tuberculosis should 
provide at least three sputum specimens for AFB microscopy and mycobacteria culture. 
 
 
A contact is a person who has shared the same enclosed air space (i.e., exposed) in a household or 
other enclosed environment for a prolonged period (days or weeks, not minutes or hours) with a 
person with a smear-positive and/or culture-positive pulmonary tuberculosis case.  Contacts 
exposed in this fashion to persons with smear-positive or culture-positive pulmonary tuberculosis 
are at increased risk of infection with M. tuberculosis.  The end of contact occurs when the 
tuberculosis case is isolated from others or the sputum smears become negative.   
 
Panel physicians should notify the appropriate public health authorities in their jurisdiction when 
they diagnose an applicant with pulmonary tuberculosis.  Contacts of cases who are applicants for 
U.S. immigration should be evaluated for tuberculosis disease by the panel physician.  All such 
contacts should receive a TST or IGRA. 
 
If the TST is ≥5 mm or IGRA is positive, the contact should be further evaluated with medical 
history, physical examination, and CXR.  If the contact is not started on LTBI therapy, he or she 
should receive an evaluation with medical history, physical examination, and CXR every 3 months 
until departure.   
 
If the TST is <5 mm, IGRA is negative, and the contact is not placed on prophylaxis, the TST or 
IGRA should be repeated every 3 months until ≥8 weeks after contact ends, the index case has 
negative sputum smears for 2 consecutive months, or TST becomes ≥5 mm or IGRA becomes 
positive. 
 
Contacts with clinical findings or CXR suggestive of tuberculosis disease should provide three 
sputum specimens to undergo microscopy for AFB and culture for mycobacterium.  Contacts 
diagnosed with tuberculosis disease will need to complete tuberculosis treatment prior to U.S. 
immigration. 
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Contacts who have a negative evaluation for tuberculosis disease may be cleared for travel. These 
applicants should be assigned a tuberculosis classification (Class B3 TB, Contact Evaluation).   
 
All contacts who travel <8 weeks after contact ends should receive a Class B3 TB, Contact 
Evaluation classification, and their TST or IGRA results should be documented.   
 
Contacts who travel ≥8 weeks after contact ends and have a TST or IGRA done ≥8 weeks after the 
end of contact that is <5 mm (TST) or negative (IGRA) should not receive a Class B3 TB, Contact 
Evaluation classification.  If the TST is ≥5 mm or IGRA is positive, they should receive a Class B3 
TB, Contact Evaluation classification and a Class B2 TB, LTBI Evaluation classification.   
 
Contacts who had clinical findings or CXR suggestive of tuberculosis and had a negative sputum 
analysis for AFB and mycobacteria culture should be classified as Class B1 TB, Pulmonary, as 
specified earlier in these Technical Instructions.  They would also receive a Class B3 TB, Contact 
Evaluation classification.   
 
In general, preventive therapy (i.e., treatment of LTBI) should not be initiated overseas.  Exceptional 
situations in which preventive therapy should be initiated overseas include certain pediatric contacts 
(see next paragraph) and contacts with impaired immunity (e.g., HIV infection).   
 Children <4 years of age and applicants with impaired immunity (e.g., HIV infection) who are 
contacts of a known pulmonary tuberculosis case, regardless of how that case was diagnosed, 
and who have a negative evaluation for tuberculosis disease, should begin directly observed 
preventive therapy (DOPT) regardless of TST or IGRA results. Isoniazid may be used except in 
known exposures to a tuberculosis case with MDR TB or isoniazid resistance.  Advice on other 
preventive regimens should be sought from experts identified by DGMQ.  Children and 
applicants with impaired immunity (e.g., HIV infection) receiving preventive therapy should 
have a TST or IGRA 8 weeks after conclusion of exposure to the infectious case.  Preventive 
therapy may be discontinued if the TST is <5 mm or IGRA is negative 8 weeks after conclusion 
of exposure to the infectious case.  Children and applicants may be cleared for travel while on 
preventive therapy and should be assigned a tuberculosis classification (Class B3 TB, Contact 
Evaluation) to ensure follow-up in the United States.  
 
If an applicant does not complete preventive tuberculosis treatment prior to departure, a 30-day 
supply of medication and instructions on how to take it should be given to the applicant or the 
parent or responsible adult traveling with the applicant. All pertinent documentation should indicate 
the applicant’s status so that the applicant can receive expedited follow-up upon arrival to the 
United States. 
 
Panel physicians do not need to wait to classify an applicant who are a contact to someone 
suspected of having tuberculosis disease until the person they are a contact to has culture results 
returned.  If someone leaves for the United States and you later learn that a contact of theirs has a 
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positive culture, please forward to the DGMQ office (via fax at 404-639-4441) that information 
and DGMQ can forward the contact information to the receiving health department.   
Technical Instructions for Panel Physicians   
Tuberculosis Classifications and Descriptions 
 
 
Applicants should be assigned one or more tuberculosis classifications  
on the DS Forms.      
 
 
The tuberculosis classifications and descriptions are listed below.  Applicants may have more than 
one TB Classification.  However, they cannot be classified as both Class B1 TB and Class B2 TB. In 
addition, applicants cannot be classified as Class B3 TB, Contact Evaluation if they are Class A or 
Class B1 TB, Extrapulmonary.    
 
No TB Classification 
Applicants with normal tuberculosis screening examinations. 
 
Class A TB with waiver 
All applicants who have tuberculosis disease and have been granted a waiver. 
 
Class B1 TB, Pulmonary 
No treatment 
 Applicants who have medical history, physical exam, or CXR findings suggestive of pulmonary 
tuberculosis but have negative AFB sputum smears and cultures and are not diagnosed with 
tuberculosis or can wait to have tuberculosis treatment started after immigration. 
Completed treatment  
 Applicants who were diagnosed with pulmonary tuberculosis and successfully completed directly 
observed therapy prior to immigration. The cover sheet should indicate if the initial sputum 
smears and cultures were positive and if drug susceptibility testing results are available.  
 
Class B1 TB, Extrapulmonary 
Applicants with evidence of extrapulmonary tuberculosis.  The anatomic site of infection should be 
documented.  
 
Class B2 TB, LTBI Evaluation 
Applicants who have a tuberculin skin test ≥10 mm or positive IGRA but otherwise have a negative 
evaluation for tuberculosis.  The size of the TST reaction or IGRA result, the applicant’s status with 
respect to LTBI treatment, and the medication(s) used should be documented.  For applicants who 
had more than one TST or IGRA, all dates and results and whether the applicant’s TST or IGRA 
converted should be documented.  Contacts with TST ≥5 mm or positive IGRA should receive this 
classification (if they are not already Class B1 TB, Pulmonary).   
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Class B3 TB, Contact Evaluation 
Applicants who are a recent contact of a known tuberculosis case. The size of the applicant’s TST 
reaction or IGRA response should be documented. Information about the source case, name, alien 
number, relationship to contact, and type of tuberculosis should also be documented. 
Technical Instructions for Panel Physicians   
Documentation 
 
 
All medical documentation, including original laboratory reports,  
must be included with the required DS Forms.  
 
 
 
All required medical documentation should be sent by courier or other secure means to 
the U.S. Embassy for all Class A and Class B1 conditions.  All Class A and Class B1 
tuberculosis conditions should be reported to the U.S. Embassy upon detection.  
 
 
 
All data that can be submitted electronically to CDC/DGMQ  
should be sent at the time of departure. 
 
 
Department of State forms DS-2054, DS-3025, DS-3026, and DS-3030 must be completed in their 
entirety and included in the applicant’s travel packet. This includes assigning a tuberculosis 
classification on the DS-2054 and DS-3030.  Incomplete documentation may result in refusal to 
grant a visa or designation of medical hold status at arrival to ports of entry. 
 
For applicants requiring tuberculosis treatment prior to U.S. immigration, the panel physician is 
required to document the following: 
1. Chest radiograph findings before, during, and after treatment as recorded on the DS 3030. 
2. Tuberculin skin test documentation should include date of TST reading, name of product, 
expiration date, amount administered, and the type of product used (e.g., 5TU PPD-S), and 
results in millimeters of induration. 
3. Interferon Gamma release assay results should include type of IGRA used (i.e., 
Quantiferon® or T-SPOT®), expiration date, and test result including units of 
measurement. 
4. Sputum smear AFB microscopy results obtained before, during, and after treatment. 
5. Cultures for mycobacteria results obtained before, during, and after treatment, including 
cultures that were contaminated. 
6. Drug susceptibility test results performed on any positive cultures. 
7. DOT regimen received (including doses of all medications), start date, and completion date, 
and any periods of interruption. 
8. Clinical course such as clinical improvement or lack of improvement during and after 
treatment, including resolution of symptoms and signs and weight stability or gain. 
9. Pre-departure screening evaluations, when required by CDC (screening that is performed 
within 3 weeks of departure). 
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APPENDIX A GLOSSARY OF ABBREVIATIONS 
 
ATS American Thoracic Society 
BCG Bacille Calmette-Guérin 
CDC Centers for Disease Control and Prevention, United States 
CXR Chest radiograph 
DGMQ Division of Global Migration and Quarantine 
DOPT Directly observed preventive therapy 
DOT Directly observed therapy 
DST Drug-susceptibility testing 
DTBE Division of Tuberculosis Elimination 
FDA U.S. Food and Drug Administration 
GAP Global AIDS Program 
GDF WHO Global Drug Facility 
HEPA High-efficiency particulate air (filter) 
HIV Human immunodeficiency virus 
IDA International Dispensary Association 
IDSA Infectious Diseases Society of America 
IGRA Interferon gamma release assay 
LTBI Latent tuberculosis infection 
MDR TB  Multidrug-resistant tuberculosis 
PPD Purified protein derivative 
QFT-G QuantiFERON®-TB Gold test 
TST Tuberculin skin test 
WHO World Health Organization 
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APPENDIX B DEFINITIONS 
 
Contact – a person who has shared the same enclosed air space (i.e., exposed) in a household or 
other enclosed environment for a prolonged period (days or weeks, not minutes or hours) with a 
person with a smear- and/or culture-positive pulmonary tuberculosis case.  Contacts exposed in this 
fashion to persons with smear- or culture-positive pulmonary tuberculosis are at increased risk of 
infection with M. tuberculosis.   
Directly observed therapy (DOT) –  adherence-enhancing strategy in which a health-care worker 
or other trained person watches a patient swallow each dose of medication.  Directly observed 
therapy is the standard care for all applicants with tuberculosis disease. 
Drug susceptibility test (DST) – a laboratory determination to assess whether an M. tuberculosis 
complex isolate is susceptible or resistant to antituberculosis drugs that are added to mycobacterial 
growth medium or are detected genetically.  The results predict whether a specific drug is likely to be 
effective in treating tuberculosis disease caused by that isolate.  
Extensively drug-resistant tuberculosis disease (XDR TB) – tuberculosis disease caused by M. 
tuberculosis organisms that are resistant to isoniazid and rifampin, plus resistance to any 
fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or 
capreomycin). 
Extrapulmonary tuberculosis –  tuberculosis disease in any part of the body other than the lungs 
(e.g., kidney, spine, or lymph nodes).  The presence of extrapulmonary disease does not exclude 
pulmonary tuberculosis disease.  Disease of the lung parenchyma may occur concurrently with 
pleural tuberculosis, and the parenchymal lung disease may not be apparent on chest radiograph due 
to compression of affected lung tissue by pleural fluid.  For the purpose of this document, 
pulmonary tuberculosis refers to both disease of the lung parenchyma and pleura and laryngeal 
tuberculosis. 
Interferon gamma release assay (IGRA) – blood tests that measure a component of cell-
mediated immunity reactivity to M. tuberculosis in fresh whole blood.   
Infection with M. tuberculosis – in some persons who are exposed to and who inhale M. 
tuberculosis bacteria, the bacteria are not promptly cleared by respiratory defense systems and multiply 
and are spread throughout the body, thereby infecting the exposed person.  In most persons who 
become infected, the body is able to fight the bacteria to stop them from growing, further 
establishing a latent state.  In latent infection, the bacteria are inactive, but they remain alive in the 
body and can become active later.  In other persons, the infection with M. tuberculosis can progress to 
tuberculosis disease more promptly.  M. tuberculosis infection encompasses both latent tuberculosis 
infection and tuberculosis disease.   
Latent tuberculosis infection (LTBI) – infection with M. tuberculosis without symptoms or signs 
of disease manifested.   
Multidrug-resistant TB (MDR TB) – tuberculosis disease caused by M. tuberculosis organisms that 
are resistant to at least isoniazid and rifampin.   
M. tuberculosis culture – a laboratory test in which the organism is grown from a submitted 
specimen (e.g., sputum) to determine the presence of M. tuberculosis.  In the absence of cross-
contamination, a positive culture confirms the diagnosis of tuberculosis disease. 
Pulmonary tuberculosis – tuberculosis disease that occurs in the lung parenchyma, usually 
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producing a cough that lasts >3 weeks.  For the purpose of this document, pulmonary tuberculosis 
refers to both disease of the lung parenchyma and pleura and laryngeal tuberculosis. 
Pre-immigration medical screening – the medical evaluation required of all applicants. 
Pre-departure screening evaluations – the medical evaluation performed within 3 weeks of 
departure for applicants with equivocal results (e.g., findings suggestive of tuberculosis on medical 
history, physical exam, or CXR, but no positive sputum smears or positive cultures).  These 
applicants should have an evaluation consisting of medical history, physical exam, CXR, and three 
sputum specimens for AFB microscopy (but no cultures required) within 3 weeks prior to departure.  
See Appendix F.   
Successfully completed tuberculosis therapy – Therapy for tuberculosis disease taken for the full 
duration of therapy, including the total number of recommended doses within the time frame 
specified in ATS/CDC/IDSA Guidelines. 
Tuberculosis disease – condition caused by infection with a member of the M. tuberculosis complex 
that has progressed to causing clinical (manifesting symptoms or signs) or subclinical (early state of 
disease in which signs or symptoms are not present, but other indications of disease activity are 
present) illness.  The bacteria can attack any part of the body, but disease is most commonly found 
in the lungs (pulmonary tuberculosis).  Pulmonary tuberculosis disease can be infectious, whereas 
extrapulmonary disease is not infectious, except in rare circumstances.   
 
APPENDIX C SPUTUM COLLECTIONS  
 
Sputum Collection 
 Sputum specimens of 5 – 10 mL 
 Preferably early morning specimens 
 Three specimens must be collected at least 24 hours apart, preferably on consecutive 
days 
 Should be directly observed 
 Applicants should rinse their mouths with purified water before providing a sputum 
specimen. 
 
Sputum Specimen Transport 
 Samples should be transported to the laboratory promptly 
 If not transported within 1 hour, samples should be refrigerated (but not frozen) 
 Ideally, specimens received in the laboratory should be processed within 24 hours of 
receipt 
 Salivary specimens are unacceptable.  The collection of a true sputum specimen is of 
critical importance if the organism is to be isolated.  
 
Sputum Specimen Processing 
 Sputum specimens should undergo centrifugation before smears are performed. 
 
Use of Induced Sputum 
 For patients who have difficulty producing sputum, there are several methods of 
obtaining a specimen.  Inhalation of an aerosol of sterile hypertonic saline (3% – 
15%), usually produced by an ultrasonic nebulizer, can be used to stimulate the 
production of sputum.  Even though aerosol-induced specimens may appear thin 
and watery, they should be processed.  The specimen should be clearly labeled as 
“induced sputum” so it will not be discarded by the laboratory as an 
inadequate specimen.  Even when alternative methods are used, three specimens 
are required at least 24 hours apart, preferably on consecutive days. 
 Sputum induction can be used for children as young as 3 years of age. 
 A gastric aspirate specimen can be used for all ages (but sputum preferable in adults) 
and may be especially helpful in young children. 
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APPENDIX D  USEFUL WEB LINKS 
 
WHO guidance on laboratory standards:  
http://www.phppo.cdc.gov/dls/ila/TB_Toolbox.aspx 
 
ATS/CDC/IDSA treatment guidelines:  
http://www.cdc.gov/tb/pubs/mmwr/Maj_guide/Treatment.htm   
 
Francis J. Curry Center and California Department of Health Services “Drug-resistant 
tuberculosis:  a survival guide for clinicians:”  
http://www.nationaltbcenter.edu/products/product_details.cfm?productID=WPT-11  
 
Oxford Immunotec, manufacturers of T-SPOT®:  http://www.oxfordimmunotec.com/  
 
Cellestis, manufacturers of QuantiFERON-TB Gold®:  http://www.cellestis.com/  
 
DGMQ TB TI website:  http://www.cdc.gov/ncidod/dq/panel_2007.htm  
 
International Panel Physicians Association website:  http://www.panelphysicians.org/  
 
WHO tuberculosis yearly report:  http://www.who.int/mediacentre/factsheets/fs104/en/ 
 
WHO Guidance for national tuberculosis programmes on the management of tuberculosis 
in children:  http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf 
 
International Standards for Tuberculosis Care:  
http://www.who.int/tb/publications/2006/istc_report.pdf 
 
CDC tuberculosis:  http://www.cdc.gov/tb/ 
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APPENDIX E.  ADDITIONAL INSTRUCTIONS FOR LARGE 
REFUGEE RESETTLEMENTS 
 
The following instructions apply for refugees being resettled to the United States.  In refugee 
emergencies, tuberculosis may not be addressed in this manner. 
 
Refugee populations 
Refugees are commonly reported to have elevated rates of tuberculosis.  Because many 
refugees live in large camps that may have crowded living conditions, the potential exists for 
outbreaks of tuberculosis.  Failure to appropriately screen refugees in a timely manner and 
failure to perform contact investigations can result in refugees with tuberculosis disease 
remaining undetected, which can lead to the development of outbreaks.  Extremely elevated 
rates of tuberculosis and tuberculosis outbreaks may cause refugee movement to be stopped 
while control measures are implemented.  Moreover, elevated rates of tuberculosis or 
tuberculosis outbreaks among refugees have the potential to stigmatize these groups and 
make successful resettlement to the United States more difficult.   
 
Chest radiographs 
Chest radiographs should be performed as soon as possible after the medical screening. 
Documentation of the results for the chest radiographs should be available within 1 week 
from the time the CXR was performed. 
 
Contact investigations 
When cases of tuberculosis are newly diagnosed, contacts should be identified and screened 
for tuberculosis disease within 2 weeks of diagnosis of the potential source case.   
 
Isolation of refugees with tuberculosis 
To minimize transmission to others, refugees with smear-positive tuberculosis should be 
relocated to an isolation area until sputum smears become negative. 
 
Waivers 
The United States is responsible for the health of refugees accepted into the United States 
Resettlement Program.  To ensure adequate care for refugees, attempts should be made to 
quickly resettle children with tuberculosis disease and refugees with difficult clinical courses.  
For refugees who are protection cases and are diagnosed with tuberculosis disease, attempts 
should be made to secure a waiver upon diagnosis so the refugees may travel as soon as they 
are smear-negative. 
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APPENDIX F  PRE-DEPARTURE EVALUATIONS 
 
Additional screening immediately prior to departure (pre-departure evaluation) 
may be required in the event of an outbreak of tuberculosis disease or in the 
setting of extremely elevated rates of tuberculosis disease. 
 
 
 
When applied, pre-departure evaluations serve as an additional measure to 
prevent importation of tuberculosis disease into the United States. 
 
 
 
If the need arises, CDC will inform the Department of State and  
panel physicians to implement pre-departure evaluations. 
 
 
When pre-departure evaluations are required, they shall be performed on applicants who are 
Class B1 TB, Pulmonary.  The evaluations shall be performed within 3 weeks of departure.  
The pre-departure evaluation shall consist of a medical history, physical examination, CXR, 
three sputum specimens for AFB microscopy (but no cultures required). 
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APPENDIX G  TUBERCULOSIS INDICATORS 
 
CDC is responsible for monitoring the effectiveness and impact of these Technical 
Instructions to diagnose applicants with tuberculosis disease.  To assist with this monitoring, 
the following tuberculosis indicators were developed.  These statistics enable panel 
physicians and CDC alike to monitor the quality of these programs.  CDC requests that 
panel physicians track these statistics and routinely report them to CDC.  The frequency of 
reporting is based on the volume of applicants examined during a typical year: 
 
 <5,000 applicants:  report yearly (January 1) 
 >5,000 applicants:  report quarterly (January 1, April 1, July 1, and October 1) 
 
CDC is available to provide technical assistance, including templates, to panel physicians 
compiling and reporting these statistics. 
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Table 2.  Tuberculosis indicators to be tracked monthly 
 
Indicator for each calendar month Definition of indicator: 
1. Number of applicants screened 
1a.  Number of applicants screened This indicator represents the total number of applicants 
screened for tuberculosis at the clinic for the month. 
 
2. Number of tuberculosis suspects 
2a.  CXR suggestive of tuberculosis This indicator represents the number of applicants screened in 
the clinic who have CXRs indicating a possible tuberculosis 
condition. 
2b.  Signs and symptoms of 
tuberculosis and normal CXR 
This indicator represents the number of applicants screened in 
the clinic who have normal CXRs BUT who have symptoms or 
other indications of a tuberculosis condition. 
2c.  HIV infection and normal CXR 
and no signs or symptoms of 
tuberculosis 
This indicator represents the number of applicants screened in 
the clinic who are HIV-infected BUT who have normal CXRs 
and no tuberculosis symptoms. 
 
2d.  TOTAL Total number of suspect tuberculosis cases for the month. The 
sum of 2a-2c should equal this total. 
 2e.  TOTAL with sputum results Total number of suspect tuberculosis cases for the month who 
provided sputum specimens for the month. 
3.  Nontuberculous mycobacteria 
3a.  Smear +/NTM This indicator represents the number of suspect tuberculosis 
cases whose sputum samples tested smear positive and whose 
culture results indicated a nontuberculosis mycobacterium. 
3b.  Smear -/NTM This indicator represents the number of suspect tuberculosis 
cases whose sputum samples tested smear negative and whose 
culture results indicated a nontuberculosis mycobacterium. 
 
3c.  TOTAL The Total number of suspect tuberculosis cases whose culture 
results indicated a nontuberculosis mycobacterium. 
4.  Extrapulmonary tuberculosis cases 
 These cases consist of patients who are diagnosed with extrapulmonary tuberculosis disease. 
  
 
4a.  Extrapulmonary tuberculosis 
Cases 
This indicator represents the number of applicants seen in the 
clinic who are diagnosed with extrapulmonary tuberculosis.   
NOTE:  An applicant who is diagnosed with both pulmonary 
and extrapulmonary tuberculosis should be counted twice, once 
as a pulmonary tuberculosis case and once as an extrapulmonary 
tuberculosis case. 
5.  Pulmonary TB Cases: 
 As of the reporting date, the number of pulmonary cases diagnosed among suspect tuberculosis 
cases screened during the reported month. 
5a.  Smears Pending This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum smear results are still unknown at the time of 
reporting. 
5b.  Smear + /Culture + This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum smears tested both smear positive and culture 
positive. 
 
5c.  Smear +/Culture - This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested smear positive but culture 
negative. 
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5d.  Smear -/Culture + This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested smear negative but culture 
positive. 
5e.  Smear -/Culture - This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested both smear negative and culture 
negative. 
5f.  Smear +/Culture pending This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested smear positive and whose culture 
results are still unknown. 
5g. Smear -/Culture pending This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested smear negative and whose culture 
results are still unknown. 
5h. Smear +/Culture contamination This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested smear positive and whose cultures 
results were contaminated. 
5i.  Smear -/Culture contamination This indicator represents the number of applicants screened at 
the clinic who were diagnosed with pulmonary tuberculosis and 
whose sputum samples tested smear negative and whose 
cultures results were contaminated. 
5j.  TOTAL Total number of pulmonary tuberculosis cases for the month. 
The sum of 5a-5i should equal this total. 
6. Drug Susceptibility Testing (DST) Results: 
 Among pulmonary TB cases with positive cultures, these are the DST results. 
6a.  DST Pending This indicator represents the number of pulmonary cases whose 
DST results are still being processed, results currently unknown. 
6b. Pansusceptible This indicator represents the number of pulmonary cases whose 
DST results were specified as ‘pansusceptible’ (susceptible to all 
tested drugs). 
6c. INH monoresistance This indicator represents the number of pulmonary cases whose 
DST results were specified as only resistant to INH. 
6d. RIF monoresistance This indicator represents the number of pulmonary cases whose 
DST results were specified as only resistant to RIF. 
6e. MDR TB This indicator represents the number of pulmonary cases whose 
DST results were specified as ‘MDR TB’. 
6f. XDR TB This indicator represents the number of pulmonary cases whose 
DST results were specified as ‘XDR TB’. 
6g. Poly-resistant but not MDR TB 
or XDR TB 
This indicator represents the number of pulmonary cases whose 
DST results were specified as ‘poly-resistant’ (resistant to many 
drugs) but not categorized as MDR or XDR TB. 
6h. Monoresistant to a drug other 
than INH  or RIF 
This indicator represents the number of pulmonary cases whose 
DST results were specified as resistant to only one drug other 
than INH or RIF. 
 
6i. TOTAL 
 
 
Total number of DST results obtained during the month. The 
sum of 6a-6g should equal this total.  Also, this total should 
equal the total number of pulmonary tuberculosis cases with 
positive cultures. 
7.  Pulmonary Tuberculosis Treatment:   
 This indicator represents current treatment status of the tuberculosis cases diagnosed within the 
month being reported. 
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7a.  Currently under treatment (<12 
months) 
This indicator represents the number of patients who are 
currently under treatment and have who have been under 
treatment for less than 12 months. 
This indicator represents the number of patients who are 
currently under treatment and have who have been under 
treatment for greater than or equal to 12 months. 
7b.  Currently under treatment 
(>12months) 
7c.  Treatment completed (<12 
months) 
This indicator represents the number of patients who had been 
on treatment for less than or equal to 12 months and have 
completed treatment. 
7d.  Cure This indicator represents the number of patients who were 
specified as ‘cured’. 
7e.  Default This indicator represents the number of patients who refused or 
defaulted treatment. 
7f.  Death This indicator represents the number of patients who died. 
7g.  Transfer out This indicator represents the number of patients who 
‘transferred out’ to another program or to another facility. 
7h.  Did not register This indicator represents the number of patients who did not 
register at a DMGQ-approved DOT site.   
 
7h.  TOTAL Total number patients who have undergone pulmonary TB 
treatment during the month. The sum of 7a-7g should equal this 
total. 
8.  Percent of patients with culture conversion: 
8a.  Percentage of patients with 
culture-positive pulmonary 
tuberculosis (excluding MDR 
TB/XDR TB) with culture 
conversion within 90 days of 
starting therapy for the month 
This indicator represents the number of patients with culture-
positive pulmonary tuberculosis (excluding MDR TB/XDR TB) 
with culture conversion within 90 days of starting therapy for 
the month, divided by the total number patients with culture-
positive pulmonary tuberculosis (excluding MDR TB/XDR 
TB). 
 
9.  Pulmonary tuberculosis treatment for persons on treatment at the time of reporting: 
 9a.  Currently under treatment (<12 
months) 
This indicator represents the number of patients who are 
currently under treatment and who have been under treatment 
for less than 12 months in your facility/program. 
 9b.  Currently under treatment 
(>12months) 
This indicator represents the number of patients who are 
currently under treatment and who have been under treatment 
for greater than or equal to 12 months in your facility/program. 
 9c.  Default This indicator represents the number of patients who refused or 
defaulted treatment in your facility/program.  
 9d. TOTAL Total number of patients who have undergone pulmonary 
tuberculosis treatment in your facility/program. The sum of 9a-
9c should equal this total.  
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